Grünenthal selects Patheon to develop drugs using INTAC abuse deterrent formulations technology Read more
DNAtrix’s Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation for Treating Malignant Brain Tumors Read more